SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transoceans pending Valaris merger and offshore contract growth are driving discussion, with traders pointing to regulatory progress, rising day rates and a larger backlog as potential supports for the combined company. Bullish hopes for a short squeeze and improved earnings are tempered by concerns about merger dilution, heavy debt and RIGs inconsistent share-price action.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks quarterly results and outlook are driving discussion: earnings and comparable sales beat expectations, but revenue missed, with the China restructuring weighing on reported sales, and shares declined. Bulls point to improving U.S. traffic and turnaround progress, while bears focus on the revenue miss, soft reported growth outlook and valuation.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

NNE is drawing attention amid a steep selloff shared by other speculative nuclear and small-modular-reactor stocks, with traders debating whether the decline reflects sector-wide weakness or concerns about the companys early-stage, pre-revenue business and execution risks. Some are buying the dip on the long-term nuclear-power and AI data-center demand thesis, while others remain bearish after the sustained losses.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

MPC is drawing attention amid a powerful rally in refiners, with traders pointing to elevated crack spreads and tight refined-fuel supplies tied to geopolitical disruptions as support for refinery margins. The community is split between bullish momentum and expectations of a pullback, with some questioning whether unusually strong margins can last after the sectors sharp run.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Strong quarterly results and outlook, along with Energy Transfers comments on natural-gas infrastructure opportunities for data centers and another distribution increase, are driving attention. Traders are broadly bullish on AI-related gas demand and income potential, though some are frustrated by the unit prices muted reaction.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention as shares reach fresh 52-week highs ahead of an expected, but unconfirmed, Q3 report, with traders watching BRIUMVIs sales momentum and whether results support the rally. Buyout and short-squeeze speculation is adding to bullish sentiment, though some traders see earnings and the commercial growth storynot an acquisitionas the main driver.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is drawing attention as a proxy for private AI holdings, especially amid speculation about a potential Anthropic IPO. Bulls see the listing as a catalyst, while bears question the funds premium to NAV and point to dilution and claims that it reduced its Anthropic stake.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A sharp selloff has put AEHRs valuation and upcoming fiscal first-quarter results in focus, with traders weighing broader weakness in AI and semiconductor stocks against concerns about the companys steep growth expectations. Bears point to put-heavy options activity and downside risk, while bulls argue the pullback may be overdone if AI chip-testing demand and FY2027 guidance hold up.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare reimbursement could fall sharply during 2027 has fueled concern about pricing and CorMedixs largest revenue driver. Traders are split between viewing the comments as a serious commercial risk and arguing that DaVitas estimates are preliminary and do not establish future CMS rates or company revenue.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through North America and International Personal Care segments. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Dallas, TX.

Kimberly-Clark Corp.

Kimberly-Clark is drawing attention after preliminary Q3 results topped expectations and the company reaffirmed its outlook; traders also point to easing Huggies-related concerns in China and progress toward financing and regulatory approval for the Kenvue acquisition. Reactions are constructive around defensive-staples demand and the mergers potential, though some remain wary of deal execution and the stocks recent weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Carlsmed Appoints Richard Heppenstall As CFO; Backs Annual Revenue Outlook

(RTTNews) - Carlsmed, Inc. (CARL), a medical technology company, said on Monday that it has appointed Richard Heppenstall as chief financial officer with immediate effect. Heppenstall will succeed Leo Greenstein, who has decided to leave the company to pursue other professional o...

Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates

Carlsmed, Inc. (CARL) delivered earnings and revenue surprises of +2.50% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -26.09% and -9.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Carlsmed, Inc. (CARL) Report Negative Earnings Next Week? What You Should Know

Carlsmed, Inc. (CARL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 51.94% Upside in Carlsmed, Inc. (CARL): Can the Stock Really Move This High?

The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?

Here is how Align Technology (ALGN) and Carlsmed, Inc. (CARL) have performed compared to their sector so far this year.

Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet

The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BTIG Research Reiterates Buy Rating for Carlsmed (NASDAQ:CARL)

BTIG Research reiterated a 'buy' rating and set a $23.00 price target on shares of Carlsmed in a research note on Wednesday...

Carlsmed Q1 Earnings Call Highlights

Carlsmed (NASDAQ:CARL) reported first-quarter 2026 revenue of $16.1 million, up 58% from $10.2 million in the prior-year period, as the company highlighted continued surgeon adoption of its...

Carlsmed, Inc. engages in the development of AI based technology solutions to the medical industry. Its solutions are utilized as an information database for surgeons using traditional surgical techniques. The company was founded by Mike Cordonnier and Niall Casey in 2018 and is headquartered in Carlsbad, CA.

Carlsmed Inc

Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish

Equity

Neutral Sentiment

Goldman Sachs has started coverage of Carlsmed with a ‘Buy’ rating and a $19 price target, suggesting about 35% upside from recent levels.The research firm’s&nbsp;analyst David Roman said the firm sees “meaningful upside” for the stock thanks to Carlsmed’s differentiated technology platform and asset-light business model,&nbsp;the Fly reported.He pointed to the company’s&nbsp;salesforce expansion, its planned 2026 launch in cervical spine procedures, and a steady flow of new clinical data as important revenue drivers.The call comes after several recent milestones. Earlier this month, the Centers for Medicare &amp; Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement for cervical fusion procedures using Carlsmed’s aprevo implants.&nbsp;Starting&nbsp;in&nbsp;October, through the NTAP program, hospitals performing these procedures will be eligible for up to an additional $21,125 in reimbursement on top of standard payments.Carlsmed also reported the first cervical procedure with its aprevo device in July at UC San Diego Health, showing progress toward a U.S. launch targeted for 2026. The company’s technology is already approved for lumbar fusion surgery and uses AI-driven planning tools to design personalized implants for patients.The company had its initial public offering on July 23, raising $100.5 million at an IPO price of $15 per share. The shares dropped 3.3% on the first day of trading, closing at $14.50, valuing the company at about $384 million.&nbsp;Since then,&nbsp;<a href="https://stocktwits.com/symbol/CARL">Carlsmed’s shares</a>&nbsp;have fallen&nbsp;6.3% year-to-date. On Friday, the stock closed 2.7% lower at $13.58 before ticking up 0.5% after hours to $13.65.Carlsmed, founded in 2018, has drawn backing from B Capital Group and US Venture Partners, which together own nearly half the company. Co-founder and Chief Executive Michael Cordonnier holds a smaller stake.&nbsp;In the first quarter of 2025, the company lost $5.7 million on $10.2 million in revenue, compared with a loss of $5.4 million on $5.1 million in revenue a year earlier.On Stocktwits, retail sentiment for Carlsmed was ‘bearish’ by late Sunday, worsening from the ‘neutral’ mood seen a day ago, amid ‘normal’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Goldman Sachs has started coverage of Carlsmed (CARL) with a ‘Buy’ rating and a $19 price target. (Photo credit: Getty Images)

The company’s July IPO raised $100.5 million but shares have slipped since, closing Friday at $13.58 before edging up in after-hours trade.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.95
Prev Close	$15.77
Open	$15.80
Dividend Yield	0.00%
50-Day Moving Average	$15.03
Beta	1.12
Avg. Volume	79,258.92
PE Ratio	-11.03

52-Week High	$17.23
52-Week Low	$8.50
Market Capitalization	$408.18M
EPS (Annual)	-$1.14
Price to Book	4.83
Revenue Per Employee	$397,724.41

Feed

News

Sentiment

Earnings

Fundamentals

Info

CARL Fundamentals